ACS Chem Biol. 2011 Jan 21;6(1):95-100. doi: 10.1021/cb100267k. Epub 2010 Oct 22.
In vitro glycorandomization is a powerful strategy to alter the glycosylation patterns of natural products and small molecule therapeutics. Yet, such in vitro methods are often difficult to scale and can be costly given the requirement to provide various nucleotides and cofactors. Here, we report the construction of several recombinant E. coli prototype strains that allow the facile production of a range of small molecule glycosides. This strategy relies on the engineered promiscuity of three key enzymes, an anomeric kinase, a sugar-1-phosphate nucleotidyltransferase, and a glycosyltransferase, as well as the ability of diverse small molecules to freely enter E. coli. Subsequently, this work is the first demonstration of "in vivo glycorandomization" and offers vast combinatorial potential by simple fermentation.
体外糖基随机化是改变天然产物和小分子治疗药物糖基化模式的强大策略。然而,由于需要提供各种核苷酸和辅助因子,这种体外方法通常难以扩展并且成本高昂。在这里,我们报告了几种重组大肠杆菌原型菌株的构建,这些菌株允许轻松生产一系列小分子糖苷。该策略依赖于三个关键酶的工程杂化性,即端基激酶、糖-1-磷酸核苷转移酶和糖基转移酶,以及各种小分子自由进入大肠杆菌的能力。随后,这项工作首次展示了“体内糖基随机化”,并通过简单的发酵提供了巨大的组合潜力。